A detailed history of American Portfolios Advisors transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, American Portfolios Advisors holds 450 shares of BEAM stock, worth $11,628. This represents 0.0% of its overall portfolio holdings.

Number of Shares
450
Holding current value
$11,628
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Mar 17, 2023

BUY
$39.79 - $70.31 $17,905 - $31,639
450 New
450 $21.4 Million
Q4 2021

Mar 21, 2023

SELL
$68.02 - $99.06 $18,705 - $27,241
-275 Reduced 61.11%
175 $13.9 Million
Q3 2021

Mar 22, 2023

SELL
$84.37 - $133.6 $23,201 - $36,740
-275 Reduced 61.11%
175 $15.2 Million
Q2 2021

Mar 22, 2023

SELL
$64.12 - $128.71 $17,248 - $34,622
-269 Reduced 59.78%
181 $23.3 Million
Q1 2021

Mar 22, 2023

SELL
$71.28 - $120.75 $20,956 - $35,500
-294 Reduced 65.33%
156 $12.5 Million
Q4 2020

Mar 22, 2023

SELL
$22.24 - $95.63 $5,982 - $25,724
-269 Reduced 59.78%
181 $14.8 Million

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.82B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track American Portfolios Advisors Portfolio

Follow American Portfolios Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

News

Stay updated on American Portfolios Advisors with notifications on news.